Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbamazepine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
NCT01581918Phase 2Unknown
- Sponsor
- Centro Universitário Faculdade de Medicina do ABC
- Start
- Dec 2011
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of carbamazepine in chemotherapy-induced nausea and vomiting (CINV), sponsored by Centro Universitário Faculdade de Medicina do ABC. Primary endpoint: Efficacy of Carbamazepine at 120 hours. Status: unknown.
02
Drugs
carbamazepine
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01581918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01581918.